Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 218 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Blueprint Medicines Corporation | BPMC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 88.38 | 04:08:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 88.38 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 218 | - | 43.89 - 101.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:05:17 | formt | 178 | $ 88.38 | USD |
Blueprint Medicines Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.41B | 61.23M | - | 249.38M | -506.98M | -8.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Blueprint Medicines News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPMC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 91.47 | 93.00 | 84.33 | 87.77 | 506,921 | -3.09 | -3.38% |
| 1 Month | 89.13 | 97.00 | 84.33 | 90.72 | 586,395 | -0.75 | -0.84% |
| 3 Months | 83.23 | 101.00 | 72.24 | 87.83 | 796,943 | 5.15 | 6.19% |
| 6 Months | 50.39 | 101.00 | 43.89 | 78.96 | 834,293 | 37.99 | 75.39% |
| 1 Year | 48.62 | 101.00 | 43.89 | 68.81 | 721,525 | 39.76 | 81.78% |
| 3 Years | 94.62 | 117.86 | 37.82 | 67.52 | 648,922 | -6.24 | -6.59% |
| 5 Years | 73.65 | 125.61 | 37.82 | 71.85 | 600,510 | 14.73 | 20.00% |
Blueprint Medicines Description
| Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. |
